How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,635 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

13781. Efficacy and Safety of Adipose Stem Cells to Treat Complex Perianal Fistulas Not Associated to Crohn´s Disease

. Patient has abused alcohol or other addictive substances within 6 months of study entry. Patient has active or latent infection by HIV, HBV or HCV. Patient has undergone major surgery or sustained a severe trauma, in the investigator's judgment, within 28 days of recruitment. Patient is receiving or has received immunomodulatory treatment for reasons other than the fistula within 6 months of study entry. Patient has a malignant tumour, except for basal or squamous cell carcinoma of the skin, or has (...) Last Update Posted : June 14, 2011 Sponsor: Cellerix Information provided by: Cellerix Study Details Study Description Go to Brief Summary: Anal fistula is defined as an abnormal communication between the anal canal and the perianal skin. Adipose-derived stem cells are a new therapy for the closure of these fistulas. This study will test the safety and efficacy of ASCs (adipose stem cells) in the treatment of patients without Crohn´s disease. Condition or disease Intervention/treatment Phase Anal

2007 Clinical Trials

13782. Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

congestive heart failure No history of cardiac syncope No recurrent symptomatic arrhythmias No oxygen-dependent restrictive cardiomyopathy No myocardial infarction within the past 6 months Pulmonary diffusion capacity > 50% predicted by pulmonary function testing No uncontrolled infection No other active malignancy, except for any of the following: Adequately treated basal cell or squamous cell skin cancer In situ cervical cancer Adequately treated stage I cancer from which the patient is currently (...) amyloidosis is to see how well treatment with IV melphalan works and then, if some clonal plasma cells are still present about 2 to 3 months after melphalan treatment, to see how well treatment with bortezomib and dexamethasone works to reduce the rest of the clonal plasma cell disease. Condition or disease Intervention/treatment Phase Multiple Myeloma and Plasma Cell Neoplasm Drug: bortezomib Drug: dexamethasone Phase 2 Study Design Go to Layout table for study information Study Type : Interventional

2007 Clinical Trials

13783. Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma

). If the apheresis collection is inadequate based on this criteria, the patient will be removed from protocol and a marrow harvest may be performed A history of a second malignancy (other then squamous cell/ basal cell carcinoma of the skin or cervical dysplasia) must be reviewed by the Principal Investigator, before inclusion or exclusion in the study. Based upon the PI's review, this patient may be eligible (i.e., distant past history of a malignancy) Contacts and Locations Go to Information from the National (...) Human Granulocyte Colony Stimulating Factor (GM-CSF) immediately following Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) will enhance anti-tumor immune reconstitution and improve outcome of Multiple Myeloma patients. The overall hypothesis of this proposal is that immediately following APBSCT the immune reconstitution is optimal to administer "killer" cells, combined with the administration of IL-2 and GM-CSF. Condition or disease Intervention/treatment Phase Myeloma Transplant

2007 Clinical Trials

13784. The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP

cell or squamous cell skin cancer, stage I or II cancer in complete remission, or carcinoma in situ of the cervix No known HIV positive Written informed consent PRIOR CONCURRENT THERAPY: Biologic therapy : No prior antibody therapy for lymphoma Chemotherapy : 6 cycles of CHOP Endocrine therapy : Not specified Radiotherapy : No prior radiotherapy for lymphoma Surgery : No prior solid organ transplantation Exclusion Criteria: Previous antineoplastic treatment other than the 6 cycles of CHOP (...) followed by Zevalin Phase 2 Detailed Description: Diffuse large B-cell lymphomas (DLBCL) are the most common lymphoid neoplasm and account for 30% to 40% of adult non-Hodgkin lymphomas (NHL). DLCBL is a potentially curable disease. The ultimate goals of introducing new modality treatments such as monoclonal antibody (Ab)-targeted therapy are to increase complete remission (CR) rate and prolong event-free survival and overall survival.In phase II trials, it was shown that in DLBL the addition

2007 Clinical Trials

13785. Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured

to be positive for hepatitis BsAg, Hepatitis C or HIV antibody Have a prior history of uveitis or autoimmune inflammatory eye disease Have had another malignancy other than cervical carcinoma-in-situ or basal cell /squamous cancer of the skin, unless they have undergone curative therapy more than 3 years ago and are still free of detectable disease, since the effects of peptide-pulsed DC on other active cancers are unknown Contacts and Locations Go to Information from the National Library of Medicine (...) by H. Lee Moffitt Cancer Center and Research Institute: stage III melanoma stage IV melanoma recurrent melanoma mucosal melanoma Additional relevant MeSH terms: Layout table for MeSH terms Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Nevi and Melanomas Vaccines Immunologic Factors Physiological Effects of Drugs

2008 Clinical Trials

13786. Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

of the following: Adequately treated basal cell or squamous cell skin cancer In situ cervical cancer Adequately treated stage I or II cancer currently in complete remission Any cancer from which the patient has been disease-free ≥ 5 years No advanced (grade 3-4) pre-existing neuropathy No HIV positivity Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided (...) : primary systemic amyloidosis Additional relevant MeSH terms: Layout table for MeSH terms Multiple Myeloma Amyloidosis Immunoglobulin Light-chain Amyloidosis Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases Proteostasis Deficiencies Metabolic Diseases Bortezomib

2008 Clinical Trials

13787. Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant

vasectomy Disease free of prior malignancies for >= 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast Able to take aspirin 81 or 325 mg daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use Coumadin or low molecular weight heparin) All study participants must be registered into the mandatory Revlimid REMS™ program, and be willing and able to comply with the requirements (...) ( Other Identifier: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium ) First Posted: February 21, 2008 Results First Posted: April 18, 2017 Last Update Posted: May 18, 2017 Last Verified: September 2015 Additional relevant MeSH terms: Layout table for MeSH terms Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases

2008 Clinical Trials

13788. Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis

gastrointestinal (GI) sites Untreated psychiatric illness, drug/alcohol abuse Inability to give voluntary informed consent or guardian's informed consent Demonstrated lack of compliance with prior medical care Malignancy within the 2 years prior to treatment, excluding adequately treated squamous cell skin cancer, basal cell carcinoma, and carcinoma in situ; treatment must have been completed (with the exception of hormonal therapy for breast cancer) with cure/remission status verified for at least 2 years (...) inclusion criteria but may have FVC or DLCO-adjusted less than 70% plus have had an adverse event on cyclophosphamide preventing its further use (specifically hemorrhagic cystitis, leukopenia with white blood cell [WBC]< 2000 or absolute neutrophil count [ANC] < 1000 or platelet count < 100,000). Group 5: Diffuse scleroderma with disease duration less than or equal to 2 years since development of first sign of skin thickening plus modified Rodnan skin score greater than or equal to 25 plus erythrocyte

2008 Clinical Trials

13789. Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

are not eligible. This includes patients requiring anti-infective treatment during the 4 week period prior to enrollment. Patients on prophylactic anti-infective agents will be eligible provided they have no signs of active infection. Patients who are known to be HIV, Hepatitis B, or Hepatitis C positive. Patients with a history of prior malignancy other than HL or ALCL that have not been in remission for greater than 5 years, with the exception of basal or squamous skin carcinoma, cervical carcinoma in situ (...) Principal Investigator: Anas Younes, MD M.D. Anderson Cancer Center More Information Go to Layout table for additonal information Responsible Party: Xencor, Inc. ClinicalTrials.gov Identifier: Other Study ID Numbers: XmAb2513-01 First Posted: February 4, 2008 Last Update Posted: April 21, 2014 Last Verified: April 2014 Additional relevant MeSH terms: Layout table for MeSH terms Lymphoma Lymphoma, Non-Hodgkin Hodgkin Disease Lymphoma, Large-Cell, Anaplastic Neoplasms by Histologic Type Neoplasms

2008 Clinical Trials

13791. A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

oxaloacetic transaminase (AST/SGOT) and alanine transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) >2.0 × ULN or >3.0 × ULN in the presence of demonstrable liver metastases; or Serum creatinine >2.0 × ULN; Patients who are pregnant or breast-feeding; Coexistent second malignancy or history of prior solid organ malignancy within previous 3 years (excluding basal or squamous cell carcinoma of the skin, and in situ carcinoma of the cervix (CIN 1) that has been treated curatively); Any prior history (...) -0002 First Posted: January 25, 2007 Results First Posted: August 13, 2012 Last Update Posted: May 2, 2018 Last Verified: April 2018 Keywords provided by Celgene: peripheral T-cell lymphoma T-cell lymphoma romidepsin Additional relevant MeSH terms: Layout table for MeSH terms Lymphoma Lymphoma, T-Cell Lymphoma, T-Cell, Peripheral Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin

2007 Clinical Trials

13792. Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma

, or bone fracture Concomitant malignancies or previous malignancies within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. Patient is pregnant or nursing Patient is receiving other investigational drugs Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided (...) by (Responsible Party): Weill Medical College of Cornell University Study Details Study Description Go to Brief Summary: Primary Objective 1. To evaluate the safety profile of Bevacizumab (Bevacizumab™)- Rituximab (Rituxan®)-CHOP (RA-CHOP) in patients with newly diagnosed mantle cell lymphoma (MCL). Secondary Objectives To evaluate the response rate and time to disease progression of the RA-CHOP regimen in patients with newly diagnosed MCL. To prospectively characterize the angiogenic profiles of MCL patients

2006 Clinical Trials

13793. Depletion of CD4+ cells exacerbates the cutaneous response to acute and chronic UVB exposure. Full Text available with Trip Pro

Depletion of CD4+ cells exacerbates the cutaneous response to acute and chronic UVB exposure. Solid organ transplant recipients have a 60-250-fold increased likelihood of developing sunlight-induced squamous cell carcinoma (SCC) compared with the general population. This increased risk is linked to the immunosuppressive drugs taken by these patients to modulate T cell function, thus preventing organ rejection. To determine the importance of T cells in the development of cutaneous SCC, we (...) examined the effects of selectively depleting Skh-1 mice of systemic CD4+ or CD8+ T cells, using monoclonal antibodies, on ultraviolet B (UVB) radiation-induced inflammation and tumor development. Decreases in systemic CD4+ but not CD8+ T cells significantly increased and prolonged the acute UVB-induced cutaneous inflammatory response, as measured by neutrophil influx, myeloperoxidase activity, and prostaglandin E2 levels. Significantly more p53+ keratinocytes were observed in UVB-exposed CD4-depleted

2007 Journal of Investigative Dermatology

13794. A human papillomavirus-associated disease with disseminated warts, depressed cell-mediated immunity, primary lymphedema, and anogenital dysplasia: WILD syndrome. Full Text available with Trip Pro

A human papillomavirus-associated disease with disseminated warts, depressed cell-mediated immunity, primary lymphedema, and anogenital dysplasia: WILD syndrome. Epidermodysplasia verruciformis (EV) is a rare genodermatosis associated with infections with specific human papillomaviruses (HPVs) belonging to the beta genus of HPV. Patients with EV usually have a selective defect in cell-mediated immunity. Although skin cancer frequently develops in the sun-exposed cutaneous lesions of patients (...) with EV, the anogenital area is usually not affected by squamous cell carcinomas related to mucosal HPV types.We report the case of a patient with clinical similarities to EV who also presented with primary lymphedema, anogenital dysplasias, and depressed cell-mediated immunity. Swab samples and biopsy specimens from various body sites collected over a 28-month period were screened by different protocols for DNA of the HPV groups alpha, beta, and mu/nu. Seventeen alpha-HPV types could be demonstrated

2008 Archives of Dermatology

13795. A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer

of malignancies other than squamous or basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix. Setting The clinical study was conducted at 23 institutions in the United States providing outpatient chemotherapy. The economic analysis was conducted in East Brunswick, New Jersey, USA. Dates to which data relate Data for the effectiveness study were collected between May 1992 and September 1993. Resource and cost data were derived from publications between 1992 and 1996. The price date (...) Protocols /economics /therapeutic use; Carcinoma, Small Cell /drug therapy /economics; Cisplatin /administration & Costs and Cost Analysis; Economics, Pharmaceutical; Etoposide /administration & Humans; Lung Neoplasms /drug therapy /economics; Models, Economic; Organophosphorus Compounds /administration & derivatives /economics; dosage /analogs & dosage /economics; dosage /economics AccessionNumber 21997000196 Date bibliographic record published 31/08/1999 Date abstract record published 31/08/1999 NHS

1996 NHS Economic Evaluation Database.

13796. Hemiscrotectomy with contralateral testicular transposition for scrotal cancer. (Abstract)

with squamous cell carcinoma and 1 with extramammary Paget's disease. After excision of the hemiscrotum affected by the tumor, which includes all layers of the scrotal wall, the testis is transposed into the contralateral hemiscrotum through a slit made in the medial scrotal septum. The defect is easily closed by apposing the surgical wound edges.The 3 men were disease-free 8, 7 and 4 years after surgery, respectively. After intervention they remained pain-free. None had hydrocele or epididymitis secondary (...) Hemiscrotectomy with contralateral testicular transposition for scrotal cancer. Wide excision of scrotal tumors results in serious defects to such an extent that in some cases the contents of the scrotum cannot be preserved. We describe a hemiscrotectomy technique with transposition of the testis to the contralateral hemiscrotum that facilitates closure of the surgical wound and allows preservation of the testis.Our procedure was used in 3 patients with scrotal neoplasia, including 2

2002 Journal of Urology

13797. Bilateral multiple pulmonary metastases in a patient with double advanced cancer of the head and neck. (Abstract)

. Histopathological examination of the primary cancer and the upper and middle cervical nodes (n = 7) indicated a diagnosis of squamous cell carcinoma. Sections of the lower cervical nodes (n = 5) revealed well-differentiated thyroid carcinoma, suggesting that the mediastinal and pulmonary lesions were of thyroid origin. After total thyroidectomy and mediastinal dissection followed by treatment with radioiodine, the multiple pulmonary nodules disappeared. There has been no evidence of recurrent tumour for 5 years. (...) Bilateral multiple pulmonary metastases in a patient with double advanced cancer of the head and neck. A case of advanced gingival cancer is described. The cancer invaded into the mandible and skin of the cheek and was associated with cervical lymph node metastases, mediastinal lymph node metastases, and bilateral multiple pulmonary metastases. The patient received neoadjuvant chemoradiotherapy and local immunotherapy, followed by curative surgery for the primary and neck lesions

2003 International Journal of Oral and Maxillofacial Surgery

13798. Familial and second lung cancers: a nation-wide epidemiologic study from Sweden. (Abstract)

in family members. Additionally, SIRs for second lung cancers were analyzed. SIRs in offspring for all lung cancer were increased to 1.87 (95% CI 1.66-2.10), adenocarcinoma to 2.15 (1.77-2.59) and squamous cell carcinoma to 1.86 (1.39-2.44) when a parent presented with lung cancer. The familial risk was not dependent on diagnostic age. Lung cancer associated with parental rectal, cervical, kidney, urinary bladder and endocrine gland cancer. The population attributable fraction of familial lung cancer (...) Familial and second lung cancers: a nation-wide epidemiologic study from Sweden. The role of hereditary factors in tumor development has been less well understood for lung cancer than for many other human neoplastic diseases. The nation-wide Swedish Family-Cancer Database was used on 10.2 million individuals and 4524 lung cancers to calculate standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for histological subtypes of lung cancer in 0-66-year-old offspring by cancers

2003 Lung Cancer

13799. Level of education and the risk of cancer in Sweden. (Abstract)

; the comparison group was the largest group, those with <9 years of education. Cancers were followed from years 1971 to 1998. Total cancer risks did not differ much, but at individual sites, the trend was significant, either increasing or decreasing over all educational groups (for 27 of 29 male and 28 of 31 female cancers). University graduates had a decreased risk of tobacco-, alcohol-, and genital infection-related cancers, but male graduates had an excess of colon, prostate, squamous cell skin, nervous (...) Level of education and the risk of cancer in Sweden. It is well known that certain cancers have shown clusteringin educational and socioeconomic groups, but recent comprehensive data on clustering by education are limited. We determined standardized incidence ratios (SIRs), adjusted for several variables, for cancer among men and women in six educational groups based on the Swedish Family-Cancer Database. People were identified with a certain educational background in the census of year 1970

2003 Cancer Epidemiology & Biomarkers and Prevention

13800. Polymorphisms in DNA repair genes and associations with cancer risk. (Abstract)

between such polymorphisms and risk of cancer. Thirty studies of polymorphisms in OGG1, XRCC1, ERCC1, XPC, XPD, XPF, BRCA2, and XRCC3 were identified in the April 30, 2002 MEDLINE database (National Center for Biotechnology Information. PubMed Database: http://www.ncbi.nlm.nih.gov/entrez). These studies focused on adult glioma, bladder cancer, breast cancer, esophageal cancer, lung cancer, prostate cancer, skin cancer (melanoma and nonmelanoma), squamous cell carcinoma of the head and neck (...) Polymorphisms in DNA repair genes and associations with cancer risk. Common polymorphisms in DNA repair genes may alter protein function and an individual's capacity to repair damaged DNA; deficits in repair capacity may lead to genetic instability and carcinogenesis. To establish our overall understanding of possible in vivo relationships between DNA repair polymorphisms and the development of cancer, we performed a literature review of epidemiological studies that assessed associations

2002 Cancer Epidemiology & Biomarkers and Prevention

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>